Noctiva (desmopressin acetate) is a non-preferred product and will only be considered for coverage under the pharmacy benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

### NOCTURIA (DUE TO NOCTURNAL POLYURIA)

For *initial* authorization:
1. Member is 50 years of age or older; AND
2. Member has documented six-month history of at least two nocturic episodes per night; AND
3. Member has documentation of at least 6 nights of 24-hour urine frequency/volume chart where nighttime urine production exceeding one-third of the total 24-hour urine production; AND
4. Member has documented normal serum sodium concentrations prior to initiating therapy and there is no history of hyponatremia per chart notes; AND
5. Member is not using Noctiva in combination with loop diuretics or with systemic or inhaled glucocorticoids; AND
6. Member does not have ANY of the following:
   a) Congestive heart failure (New York Heart Association Class II to IV);
   b) Uncontrolled hypertension;
   c) Polydipsia;
   d) Renal impairment with an estimated glomerular filtration rate (eGFR) below 50 mL/min/1.73 m².
7. **Dosage allowed:** For patients < 65 years of age who are not at increased risk for hyponatremia: Use one spray of 1.66 mcg in either nostril nightly approximately 30 minutes before going to bed. For patients ≥ 65 years of age or younger patients at risk for hyponatremia: Use 0.83 mcg nightly, which can be increased to one spray of 1.66 mcg after at least 7 days, if needed, provided the serum sodium has remained normal.

*If member meets all the requirements listed above, the medication will be approved for 3 months.*

For *reauthorization*:
1. Member must be in compliance with all other initial criteria; AND
2. Member has normal serum sodium concentrations labs submitted with chart notes.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 3 months.*

CareSource considers Noctiva (desmopressin acetate) intranasal not medically necessary for the treatment of the following disease states based on a lack of...
robust clinical controlled trials showing superior efficacy compared to currently available treatments:

- Nocturnal Enuresis
- Syndrome Of Inappropriate Antidiuretic Hormone Secretion (SIADH)

<table>
<thead>
<tr>
<th>DATE</th>
<th>ACTION/DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/12/2017</td>
<td>New policy for Noctiva created.</td>
</tr>
</tbody>
</table>

References:

Effective date: 09/01/2017
Revised date: 06/12/2017